278 related articles for article (PubMed ID: 16248986)
1. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
[TBL] [Abstract][Full Text] [Related]
2. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
Ball WA; Snavely DB; Hargreaves RJ; Szegedi A; Lines C; Reines SA
Hum Psychopharmacol; 2014 Nov; 29(6):568-77. PubMed ID: 25330122
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.
Kramer MS; Winokur A; Kelsey J; Preskorn SH; Rothschild AJ; Snavely D; Ghosh K; Ball WA; Reines SA; Munjack D; Apter JT; Cunningham L; Kling M; Bari M; Getson A; Lee Y
Neuropsychopharmacology; 2004 Feb; 29(2):385-92. PubMed ID: 14666114
[TBL] [Abstract][Full Text] [Related]
4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
5. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.
Bergström M; Hargreaves RJ; Burns HD; Goldberg MR; Sciberras D; Reines SA; Petty KJ; Ogren M; Antoni G; Långström B; Eskola O; Scheinin M; Solin O; Majumdar AK; Constanzer ML; Battisti WP; Bradstreet TE; Gargano C; Hietala J
Biol Psychiatry; 2004 May; 55(10):1007-12. PubMed ID: 15121485
[TBL] [Abstract][Full Text] [Related]
6. NK1 receptor antagonists for depression: Why a validated concept was abandoned.
Rupniak NMJ; Kramer MS
J Affect Disord; 2017 Dec; 223():121-125. PubMed ID: 28753469
[TBL] [Abstract][Full Text] [Related]
7. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder.
Ratti E; Bellew K; Bettica P; Bryson H; Zamuner S; Archer G; Squassante L; Bye A; Trist D; Krishnan KR; Fernandes S
J Clin Psychopharmacol; 2011 Dec; 31(6):727-33. PubMed ID: 22020354
[TBL] [Abstract][Full Text] [Related]
8. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with substance P receptor (NK1) antagonists in depression.
Ranga K; Krishnan R
J Clin Psychiatry; 2002; 63 Suppl 11():25-9. PubMed ID: 12562140
[TBL] [Abstract][Full Text] [Related]
10. Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies.
Ratti E; Bettica P; Alexander R; Archer G; Carpenter D; Evoniuk G; Gomeni R; Lawson E; Lopez M; Millns H; Rabiner EA; Trist D; Trower M; Zamuner S; Krishnan R; Fava M
J Psychopharmacol; 2013 May; 27(5):424-34. PubMed ID: 23539641
[TBL] [Abstract][Full Text] [Related]
11. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
12. Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
Kramer MS; Cutler N; Feighner J; Shrivastava R; Carman J; Sramek JJ; Reines SA; Liu G; Snavely D; Wyatt-Knowles E; Hale JJ; Mills SG; MacCoss M; Swain CJ; Harrison T; Hill RG; Hefti F; Scolnick EM; Cascieri MA; Chicchi GG; Sadowski S; Williams AR; Hewson L; Smith D; Carlson EJ; Hargreaves RJ; Rupniak NM
Science; 1998 Sep; 281(5383):1640-5. PubMed ID: 9733503
[TBL] [Abstract][Full Text] [Related]
13. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.
Tebas P; Spitsin S; Barrett JS; Tuluc F; Elci O; Korelitz JJ; Wagner W; Winters A; Kim D; Catalano R; Evans DL; Douglas SD
AIDS; 2015 May; 29(8):931-9. PubMed ID: 25915168
[TBL] [Abstract][Full Text] [Related]
14. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
17. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy.
Ruhé HG; Booij J; v Weert HC; Reitsma JB; Franssen EJ; Michel MC; Schene AH
Neuropsychopharmacology; 2009 Mar; 34(4):999-1010. PubMed ID: 18830236
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.
Tebas P; Tuluc F; Barrett JS; Wagner W; Kim D; Zhao H; Gonin R; Korelitz J; Douglas SD
PLoS One; 2011; 6(9):e24180. PubMed ID: 21931661
[TBL] [Abstract][Full Text] [Related]
19. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
[TBL] [Abstract][Full Text] [Related]
20. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
